Taylor & Francis Group

SHERPA: Unknown

People

  1. Tallman
    Tallman
  2. Geyer
    Geyer
  3. Stein
    Stein
  4. Goldberg
    Goldberg
  5. Park
    Park
  6. Rampal
    Rampal
  7. Scheinberg
    Scheinberg
  8. Derkach
    Derkach
  9. Levine
    Levine
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Adult Leukemia (85)
  2. Center for Hematologic Malignancies (85)
  3. Department of Medicine (85)
  4. Hematologic Malignancies, Division of (85)
  5. GSK Faculty (18)
  6. Weinberg Fellows (16)
  7. Hematologic Malignancies Research (11)
  8. Hematology-Oncology Fellows (11)
  9. Tow Center for Developmental Oncology (TCDO) (10)
  10. Center for Molecular Imaging and Biotechnology (9)
Search Within
  1. "Adult Leukemia"
Formats
  1. Journal Article (54)
  2. Review (12)
  3. Meeting Abstract (10)
  4. Editorial (5)
  5. Research Letter (2)
  6. Conference Paper (1)
  7. Correspondence (1)
Groups
  1. Adult Leukemia (85)
  2. Center for Hematologic Malignancies (85)
  3. Department of Medicine (85)
  4. Hematologic Malignancies, Division of (85)
  5. GSK Faculty (18)
  6. Weinberg Fellows (16)

More Groups

People
  1. Martin Tallman (28)
  2. Anthony Mato (18)
  3. Eytan Stein (12)
  4. Jae Park (11)
  5. Lindsey Roeker (10)
  6. Mark Geyer (9)

More People

Years
  1. 2025 (2)
  2. 2024 (4)
  3. 2023 (8)
  4. 2022 (5)
  5. 2021 (7)
  6. 2020 (20)

More Years

Publications
  1. Leukemia and Lymphoma (72)
  2. Expert Review of Hematology (5)
  3. Cancer Biology and Therapy (2)
  4. Cytokines Cellular and Molecular Therapy (2)
  5. Expert Opinion on Biological Therapy (2)
  6. Expert Opinion on Investigational Drugs (1)

More Publications

Results (85)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML
    Journal Article

    Chin, K. K.; Derkach, A.; Famulare, C.; Gupta, G. K.; Borge, P. D.; Geyer, M.; Goldberg, A. D.; Haque, T.; Park, J. H.; Roeker, L. E.; more...
    Leukemia and Lymphoma (2025)

    Fulltext@MSK | Save
  • Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: A systematic literature review
    Review

    Marks, D. I.; Cassaday, R. D.; Ribera, J. M.; Schuh, A. C.; Park, J. H.; Chiaretti, S.; Stelljes, M.
    Expert Review of Hematology (2025)

    Fulltext@MSK | Save
  • TP53 Y220C mutations in patients with myeloid malignancies
    Research Letter

    Gener-Ricos, G.; Bewersdorf, J. P.; Loghavi, S.; Bataller, A.; Goldberg, A. D.; Sasaki, K.; Famulare, C.; Takahashi, K.; Issa, G. C.; Borthakur, G.; more...
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save
  • Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia
    Journal Article

    Bewersdorf, J. P.; Patel, K. K.; Shallis, R. M.; Podoltsev, N. A.; Kewan, T.; Stempel, J.; Mendez, L.; Stahl, M.; Stein, E. M.; Huntington, S. F.; more...
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save
  • Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Focus on the use of tagraxofusp and clinical considerations
    Review

    Pemmaraju, N.; Madanat, Y. F.; Rizzieri, D.; Fazal, S.; Rampal, R.; Mannis, G.; Wang, E. S.; Foran, J.; Lane, A. A.
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save
  • Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies
    Journal Article

    Stein, E. M.; Fathi, A. T.; Harb, W. A.; Colak, G.; Fusco, A.; Mangan, J. K.
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save
  • Use of tamibarotene, a potent and selective RARĪ± agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression
    Journal Article

    Stein, E. M.; de Botton, S.; Cluzeau, T.; Pigneux, A.; Liesveld, J. L.; Cook, R. J.; Rousselot, P.; Rizzieri, D. A.; Braun, T.; Roboz, G. J.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: A review
    Review

    Locatelli, F.; Shah, B.; Thomas, T.; Velasco, K.; Adedokun, B.; Aldoss, I.; Gore, L.; Hoelzer, D.; Bassan, R.; Park, J. H.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab
    Research Letter

    Parisi, R.; Cowen, E. A.; Gu, S.; Dusza, S.; Pulitzer, M.; Geyer, M. B.; King, A. C.; Markova, A.
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: A real-world database study
    Journal Article

    Eyre, T. A.; Hess, L. M.; Sugihara, T.; He, D.; Khanal, M.; Pagel, J. M.; Walgren, R. A.; Abada, P. B.; Konig, H.; Roeker, L. E.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save